NeueHealth Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

NeueHealth wird voraussichtlich ein Umsatzwachstum verzeichnen at 2.1% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	2.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Oct 11

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Aug 13

Bright Health Group Takes Cost Actions To Effect Turnaround

Jul 21

Bright Health Group: Examining A Dumpster Fire

Jan 04

Gewinn- und Umsatzwachstumsprognosen

NYSE:NEUE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1,135	N/A	N/A	N/A	1
12/31/2024	1,005	N/A	N/A	N/A	1
3/31/2024	1,105	-510	-2,161	-2,160	N/A
12/31/2023	1,161	-563	-2,729	-2,727	N/A
9/30/2023	2,756	-1,078	-2,281	-2,273	N/A
6/30/2023	2,680	-660	-1,231	-1,216	N/A
3/31/2023	871	-447	-889	-865	N/A
12/31/2022	751	-521	207	234	N/A
9/30/2022	-1,031	-373	-71	-39	N/A
6/30/2022	-145	-513	277	312	N/A
3/31/2022	819	-450	192	223	N/A
12/31/2021	1,513	-330	52	82	N/A
9/30/2021	3,427	-534	139	165	N/A
6/30/2021	2,700	-293	336	353	N/A
3/31/2021	1,883	-266	193	204	N/A
12/31/2020	515	-161	-64	-57	N/A
12/31/2019	281	-125	-9	-8	N/A
12/31/2018	131	-63	-28	-27	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von NEUE über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von NEUE schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von NEUE in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: NEUEDie Einnahmen des Unternehmens (2.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: NEUEDie Einnahmen des Unternehmens (2.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEUE in 3 Jahren voraussichtlich hoch sein wird

NeueHealth Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

Consensus EPS estimates upgraded to US$51.32 loss

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Price target increased by 47% to US$200

Recent updates

New major risk - Financial position

NeueHealth, Inc. announced that it has received $150 million in funding

New minor risk - Shareholder dilution

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$2.31 loss per share (vs US$9.04 loss in 1Q 2023)

NeueHealth, Inc. to Report Q1, 2024 Results on May 08, 2024

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$70.72 loss per share (vs US$98.28 loss in FY 2022)

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$72.52 loss per share (vs US$40.11 loss in 3Q 2022)

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Bright Health Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Consensus EPS estimates upgraded to US$51.32 loss

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Bright Health Group, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 47% to US$200

Florence Labs, Inc. acquired Zipnosis, Inc. from Bright Health Group, Inc. (NYSE:BHG).

Price target decreased by 14% to US$1.70

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Price target decreased by 24% to US$1.50

Consensus EPS estimates fall by 14%

Full year 2022 earnings released: US$1.23 loss per share (vs US$3.02 loss in FY 2021)

Bright Health Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Bright Health Group: Stock Price Has Been Too Heavily Beaten Down

Bright Health Group expects FY23 revenue to be below consensus

Independent Director recently bought US$248k worth of stock

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Bright Health receives non-compliance notice from NYSE

Independent Lead Director recently bought US$294k worth of stock

Price target decreased to US$2.07

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2022

Bright Health Group reports Q3 mixed earnings; revises Fy22 guidance

Bright Health Group, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Bright Health Group, Inc. announced that it has received $175 million in funding from a group of investors

Bright Health Group, Inc. Provides Revenue Guidance for the Year 2023

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Provides Revenue Guidance for the Full Year 2022

Bright Health Group, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Bright Health Group Takes Cost Actions To Effect Turnaround

Price target decreased to US$2.76

Bright Health Group, Inc.(NYSE:BHG) dropped from Russell 2000 Growth Index

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Bright Health Group, Inc. to Report Q1, 2022 Results on May 04, 2022

Bright Health Group, Inc., Annual General Meeting, May 13, 2022

Consensus forecasts updated

Bright Health Group, Inc. Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Bright Health Group, Inc. Provides Earnings Guidance for the Year 2022

Bright Health Group, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Bright Health Group Announces Executive Changes, Effective March 11, 2022

Pomerantz LLP Files A Class Action Lawsuit Against Bright Health Group, Inc

Pomerantz LLP Files A Class Action Lawsuit Against Bright Health Group, Inc